Objective: To determine if the recent rapid fall in use of hormone replacement therapy (HRT) in Australia has been followed by a reduction in breast cancer incidence among women aged 50 years or older, but not among younger women.
Design and setting: Analysis of trends in annual prescribing of HRT, using Pharmaceutical Benefits Scheme data, and in annual age-standardised breast cancer incidence rates in Australian women for the period 1996–2003.
Results: In Australia, prescribing of HRT increased from 1996 to 2001, but dropped by 40% from 2001 to 2003. Age-standardised breast cancer incidence rates in women aged ≥ 50 years also increased to 2001 but declined thereafter. The incidence rates in this age group were lower by 6.7% (95% CI, 3.9%–9.3%; P < 0.001) in 2003 compared with 2001, equivalent to 600 (95% CI, 350–830) fewer breast cancers (out of about 9000 incident breast cancers annually for women this age). There was no significant change in breast cancer incidence for women aged < 50 years.
Conclusions: While other factors may have contributed to a recent reduction in breast cancer incidence among Australian women aged ≥ 50 years, the available evidence suggests that much of the decrease is due to the recent fall in use of HRT. This is consistent with other evidence that the HRT-associated increase in risk of breast cancer is reversible after ceasing use of HRT.
- 1. Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
- 2. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007; 356: 1670-1674.
- 3. Clarke CA, Glaser SL, Uratsu CS, et al. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol 2006; 24: e49-e50.
- 4. Clarke CA, Glaser SL. Declines in breast cancer after the WHI: apparent impact of hormone therapy. Cancer Causes Control 2007; 18: 847-852.
- 5. Robbins AS, Clarke CA. A decline in breast-cancer incidence. N Engl J Med 2007; 357: 511-512.
- 6. Kerlikowske K, Miglioretti DL, Buist DS, et al; National Cancer Institute-Sponsored Breast Cancer Surveillance Consortium. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 2007; 99: 1335-1339.
- 7. Glass AG, Lacey JV Jr, Carreon JD, Hoover RN. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007; 99: 1152-1161.
- 8. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among US women. Breast Cancer Res 2007; 9: R28.
- 9. Kliewer EV, Demers AA, Nugent ZJ. A decline in breast-cancer incidence. N Engl J Med 2007; 357: 509-510.
- 10. Katalinic A, Rawal R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 2008; 107: 427-430.
- 11. Johnston M. Breast cancer drop linked to fall in use of HRT. New Zealand Herald 2006; 20 Dec. http://www.nzherald.co.nz/section/story. cfm?c_id=204&objectid=10416198 (accessed Dec 2007).
- 12. Keegan TH, Chang ET, John EM, et al. Recent changes in breast cancer incidence and risk factor prevalence in San Francisco Bay area and California women: 1988 to 2004. Breast Cancer Res 2007; 9: R62.
- 13. Zahl PH, Maehlen J. A decline in breast-cancer incidence [letter]. N Engl J Med 2007; 357: 510-511.
- 14. Ponti A, Rosso S, Zanetti R, et al. Re: Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status [letter]. J Natl Cancer Inst 2007; 99: 1817-1818.
- 15. Soerjomataram I, Coebergh JW, Louwman MW, et al. Does the decrease in hormone replacement therapy also affect breast cancer risk in the Netherlands [letter]? J Clin Oncol 2007; 25: 5038-5039.
- 16. Medicare Australia. PBS Statistics [website]. http://www.medicareaustralia.gov.au/providers/health_statistics/statistical_reporting/pbs.htm (accessed Dec 2007).
- 17. Australian Government Department of Health and Ageing. Schedule of pharmaceutical benefits for approved pharmacists and medical practitioners [1996–2003]. Canberra: Department of Health and Ageing, 2003.
- 18. Australian Government Department of Health and Ageing. Australian statistics on medicines [1997–2005]. Canberra: Department of Health and Ageing, 2007. http://www.health.gov.au/internet/main/publishing.nsf/Content/health-pbs-general-pubs-asm.htm (accessed Dec 2007).
- 19. Australian Bureau of Statistics. National Health Survey: summary of results, Australia, 2001. Canberra: ABS, 2002. (ABS Cat. No. 4364.0.)
- 20. Australian Bureau of Statistics. National Health Survey: summary of results, Australia, 2004–05. Canberra: ABS, 2006. (ABS Cat. No. 4364.0.)
- 21. Australian Institute of Health and Welfare. Australian cancer incidence and mortality (ACIM) books. Canberra: AIHW, 2007.
- 22. World Health Organization. International statistical classification of diseases and related health problems, 10th revision. http://www.who.int/classifications/apps/icd/icd10online/ (accessed Dec 2007).
- 23. Australian Institute of Health and Welfare, Australasian Association of Cancer Registries. Cancer in Australia: an overview, 2006. Canberra: AIHW, 2007. (AIHW Cat. No. CAN 32.)
- 24. Advisory Committee on Breast Cancer Screening. Screening for breast cancer in England: past and future. NHSBSP Publication No 61. Sheffield: NHS Cancer Screening Programmes, 2006.
- 25. International Agency for Research on Cancer. IARC handbooks of cancer prevention Vol. 7. Breast cancer screening. Lyon: IARC Press, 2002.
- 26. Australian Institute of Health and Welfare. BreastScreen Australia monitoring report 2003–2004. Canberra: AIHW, 2007. (AIHW Cat. No. CAN 31.)
- 27. Kerlikowske K, Buist DS, Walker R. Response: Re: declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population [letter]. J Natl Cancer Inst 2007; 99: 1816-1817.
- 28. Hofvind S, Sørum R, Thoresen S. Incidence and tumor characteristics of breast cancer diagnosed before and after implementation of a population-based screening-program. Acta Oncol 2007; Sep 12: 1-7.
- 29. New Zealand Health Information Service. Cancer: new registrations and deaths [2001–2003]. Wellington: Ministry of Health, 2007.
- 30. Richardson A, Graham P, Brown T, et al. Breast cancer detection rates, and standardised detection ratios for prevalence screening in the New Zealand breast cancer screening programme. J Med Screen 2004; 11: 65-69.
- 31. Clarke CA, Robbins AS. In reply: Does the decrease in hormone replacement therapy also affect breast cancer risk in the Netherlands [letter]? J Clin Oncol 2007; 25: 5039-5040.
- 32. Robbins AS, Clarke CA. Re: Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population [letter]. J Natl Cancer Inst 2007; 99: 1815.
- 33. Medicines and Healthcare products Regulatory Agency. UK public assessment report. Hormone-replacement therapy: safety update. London: MHRA, 2007.
- 34. Medicines and Healthcare products Regulatory Agency. UK public assessment report. Tibolone (Livial): benefit-risk evaluation. London: MHRA, 2007.
- 35. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 1047-1059.
- 36. Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-427.
- 37. Coombs NJ, Taylor R, Wilcken N, Boyages J. HRT and breast cancer: impact on population risk and incidence. Eur J Cancer 2005; 41: 1775-1781.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.